Yan, Shuang <br/><br/>
Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.  [electronic resource] 

 -  Oncotarget  Mar 2013 
 - 433-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.930  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Caspases<br/>Cell Cycle--drug effects<br/>Cell Line<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Child<br/>Dose-Response Relationship, Drug<br/>Female<br/>HEK293 Cells<br/>Humans<br/>Immunoblotting<br/>Janus Kinase 2--antagonists & inhibitors<br/>Mice<br/>Mice, Nude<br/>Mice, SCID<br/>Neuroblastoma--drug therapy<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>STAT3 Transcription Factor--metabolism<br/>Sarcoma--drug therapy<br/>Signal Transduction--drug effects<br/>Survival Analysis<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays